The immunohistochemical (IHC) analysis of p16, CD3, CD8, and PD-L1 in anal cancer not only provides valuable insights into the tumor microenvironment but also serves to guide treatment decisions and prediction of patient outcomes (17). This evidence concerns the gene CD8A and anal carcinoma.